Merkel Cell Carcinoma

What Is Merkel Cell Carcinoma?

Merkel cell carcinoma, often abbreviated MCC, is a rare but highly aggressive form of skin cancer that arises from neuroendocrine cells within the skin. Although far less common than melanoma or other more familiar skin cancers, MCC is considerably more likely to spread and, historically, has carried a notably higher mortality rate than cutaneous melanoma.¹

MCC most frequently develops on skin that has received significant lifetime sun exposure, particularly the head and neck, and it typically affects older adults, with the large majority of cases diagnosed in people over the age of fifty, and nearly half occurring in those over seventy five.²

What distinguishes MCC biologically from most other skin cancers is its frequent association with a specific virus, Merkel cell polyomavirus, which is believed to directly drive tumor formation in roughly eighty percent of cases, making MCC one of relatively few human cancers with such a clearly established viral connection.³

Merkel cell carcinoma is a rare and highly aggressive neuroendocrine tumor of the skin that most commonly arises on sun exposed areas, particularly the head and neck, in older, fair skinned individuals.
National Center for Biotechnology Information

Symptoms

MCC typically presents as a firm, painless nodule that grows notably faster than most other skin growths, often appearing flesh colored, red, or violet in color and developing over a period of just weeks rather than the months to years typical of many other skin cancers.²

Because the tumor is generally painless and grows so rapidly, it can be easy to mistake for a harmless cyst, insect bite, or other benign skin change in its earliest stages, which sometimes leads to delayed recognition and diagnosis.²

MCC most commonly appears on sun exposed skin, particularly the head, neck, and arms, though it can occasionally develop in areas with less obvious sun exposure. Any new, rapidly growing skin nodule, particularly in an older adult, warrants prompt evaluation by a dermatologist.¹

Causes

The majority of MCC cases result from infection with Merkel cell polyomavirus, a common virus that most people encounter at some point in life without any resulting harm. In a small subset of infected individuals, however, the virus integrates into the DNA of skin cells and begins expressing specific viral proteins that drive uncontrolled cell growth.³

A smaller proportion of MCC cases develop independently of viral infection, instead resulting directly from cumulative DNA damage caused by ultraviolet radiation, similar to the mechanism responsible for many other forms of skin cancer.²

Because both viral integration and direct UV damage are relatively rare events at the cellular level, most people exposed to either risk factor never develop MCC, suggesting that additional factors, including a properly functioning immune system capable of controlling abnormal cell growth, play an important protective role against tumor formation.⁴

Risk Factors

Advanced age represents one of the strongest risk factors for MCC, with the large majority of cases occurring in people over fifty and risk continuing to climb substantially with each subsequent decade of life.²

Significant cumulative ultraviolet exposure, whether from natural sunlight or artificial tanning sources, along with fair skin that burns easily, both meaningfully raise individual risk, consistent with the strong association between MCC and sun exposed body areas.²

Immune system suppression represents a particularly significant risk factor. MCC occurs considerably more often in organ transplant recipients, people with HIV, and patients with certain blood cancers such as chronic lymphocytic leukemia, reflecting the immune system’s important role in normally controlling both the causative virus and any resulting abnormal cell growth.⁵

Complications

MCC has a pronounced tendency to spread beyond its original skin site, with distant spread occurring in roughly one third of patients, most commonly to lymph nodes first, followed by the liver and bone marrow in more advanced cases.⁶

Overall survival reflects this aggressive behavior, with five year survival ranging from roughly forty eight to sixty three percent across all stages combined, but dropping to just fourteen percent for patients diagnosed with distant metastatic disease, underscoring how significantly stage at diagnosis affects long term outcomes.⁶

Because MCC grows and spreads so rapidly compared with many other skin cancers, delays in diagnosis and treatment can meaningfully worsen prognosis, making prompt recognition of a rapidly growing skin nodule particularly important for this specific cancer type.¹

Treatment

For localized MCC that has not spread beyond the original tumor site, wide surgical excision followed by radiation therapy to the affected area represents the standard first line treatment approach, aiming to remove the tumor completely and reduce the risk of local recurrence.⁶

For advanced or metastatic MCC that has spread beyond the original site, immunotherapy has become the preferred first line systemic treatment, representing a significant advance over the more limited options previously available for this aggressive cancer.⁶

Avelumab, an antibody that blocks a specific immune checkpoint protein, became the first immunotherapy approved for advanced MCC in 2017, with roughly one third of patients whose cancer had not responded to prior treatment showing meaningful improvement, with responses lasting an average of ten months. Additional checkpoint inhibitors, including pembrolizumab, have since received approval for this indication as well.⁷

Prevention

Limiting cumulative ultraviolet exposure through consistent sunscreen use, protective clothing, and avoiding tanning beds represents an important preventive strategy, given the significant role UV exposure plays in many MCC cases.²

For people with a compromised immune system, whether due to organ transplantation, HIV, or certain blood cancers, regular dermatologic skin examinations are particularly important, given the significantly elevated MCC risk within this specific population.⁵

Because MCC grows so rapidly, prompt evaluation of any new, quickly enlarging skin nodule, rather than a watchful waiting approach, offers the best opportunity for early diagnosis and treatment while the cancer remains most treatable.¹

Why Visual Communication Matters for Merkel Cell Carcinoma

Explaining how a common, usually harmless virus can occasionally drive an aggressive cancer, or how immunotherapy harnesses the immune system to fight a tumor it previously failed to control, requires visuals that make this genuinely unusual cancer biology understandable to patients facing an unfamiliar and often frightening diagnosis.³

Pharmaceutical companies, oncology and dermatology practices, and patient advocacy organizations rely on precise illustration and animation to explain the biology behind MCC and the immunotherapy advances that have reshaped its treatment.

• Illustrating how Merkel cell polyomavirus integration drives tumor formation
• Animating the mechanism of action for checkpoint inhibitor immunotherapy in MCC
• Explaining why immune suppression significantly raises MCC risk
• Visualizing how MCC spreads and how staging affects treatment and prognosis
• Supporting patient education on recognizing rapidly growing skin nodules
• Creating training materials for clinicians on diagnosis and treatment planning

How Biotic Artlab Supports Merkel Cell Carcinoma Communication

We work with pharmaceutical companies, oncology and dermatology practices, and patient advocacy organizations to create accurate, engaging visuals that make this rare, aggressive cancer easier to explain to patients and clinicians alike.

• Custom 3D animations of viral oncogenesis and immune checkpoint biology
• Detailed illustrations of MCC presentation and staging
• Mechanism of action animations for immunotherapy treatments
• Patient facing educational materials on risk factors and early recognition
• Clinical training content for oncology and dermatology teams
• Conference presentations and marketing visuals for oncology audiences

Frequently Asked Questions

Is Merkel cell carcinoma contagious since it is linked to a virus?

No. While Merkel cell polyomavirus is common and can be transmitted between people, the vast majority of infected individuals never develop cancer, and MCC itself is not contagious or transmissible from an affected person to others.³

How is Merkel cell carcinoma different from melanoma?

Both are serious skin cancers, but MCC arises from different cell types, is far less common, and tends to grow and spread considerably faster than melanoma, with a historically higher mortality rate despite its lower overall incidence.¹

Who is most at risk for Merkel cell carcinoma?

Older adults, particularly those over fifty with significant lifetime sun exposure and fair skin, face elevated risk, as do people with a suppressed immune system due to organ transplantation, HIV, or certain blood cancers.⁵

How is Merkel cell carcinoma treated?

Localized tumors are typically treated with surgical removal followed by radiation therapy, while advanced or metastatic disease is generally treated with immunotherapy, which has significantly improved outcomes compared with older treatment approaches.⁶

What is avelumab and how does it work?

Avelumab is an immunotherapy medication that blocks a specific protein tumors use to evade immune detection, helping the immune system recognize and attack MCC cells more effectively. It was the first immunotherapy specifically approved for advanced MCC.⁷

Why does Merkel cell carcinoma grow so quickly?

MCC arises from neuroendocrine cells that tend to divide rapidly, and the specific molecular drivers behind the cancer, whether viral or UV related, promote particularly aggressive, fast growing tumor behavior compared with many other skin cancers.²

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to Merkel cell carcinoma or skin cancer more broadly, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information, StatPearls. Merkel Cell Carcinoma of the Skin.
2. National Center for Biotechnology Information. Merkel Cell Carcinoma, Epidemiology, Clinical Features, Diagnosis and Treatment of a Rare Disease.
3. National Center for Biotechnology Information. From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis.
4. National Center for Biotechnology Information. Merkel Cell Polyomavirus and Cutaneous Merkel Cell Carcinoma.
5. National Center for Biotechnology Information. Merkel Cell Carcinoma in Immunosuppressed Patients.
6. National Cancer Institute. Merkel Cell Carcinoma Treatment.
7. National Cancer Institute. FDA Approves Pembrolizumab to Treat Merkel Cell Carcinoma.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.